Malaysian Biotechnology Information Centre

bic.org.my

The Malaysian Biotechnology Information Centre (MABIC) is the first and only NGO that promotes biotechnology in Malaysia and enjoys excellent working relationship with ministries, government agencies, research institutes, universities, trade organizations, embassies and high commissions, media, industry and farmer organizations. MABIC’s mission is to provide scientifically accurate and fact-based resources to all stakeholders and support the government’s efforts in developing the biotechnology sector.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

Burixafor | November 09, 2020

news image

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

news image

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More

CELL AND GENE THERAPY

ADICET BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Adicet Bio, Inc. | September 06, 2022

news image

Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022. The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...

Read More

MEDICAL

BIOSYNTH CARBOSYNTH FURTHER EXPANDS LIFE SCIENCES PLATFORM WITH ACQUISITION OF AALTO BIO REAGENTS

Carbosynth | May 30, 2022

news image

Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD indust...

Read More
news image

CELL AND GENE THERAPY

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

Burixafor | November 09, 2020

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More
news image

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More
news image

CELL AND GENE THERAPY

ADICET BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Adicet Bio, Inc. | September 06, 2022

Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022. The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...

Read More
news image

MEDICAL

BIOSYNTH CARBOSYNTH FURTHER EXPANDS LIFE SCIENCES PLATFORM WITH ACQUISITION OF AALTO BIO REAGENTS

Carbosynth | May 30, 2022

Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD indust...

Read More